ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced results from a preclinical study, conducted under its collaboration with the Cancer Science Institute of Singapore (CSI Singapore) and National University Cancer Institute, Singapore (NCIS), that identifies the potential of ASLAN003 as a novel therapeutic agent for Acute Myeloid Leukaemia (AML).

The new data demonstrate ASLAN003 induces differentiation of AML blast cell lines. The induction of differentiation of AML blast cells has been linked with apoptosis, which leads to normalisation of AML bone marrow.

For more information, please refer to the Engish or Chinese press release.